Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,817
  • Shares Outstanding, K 62,870
  • Annual Sales, $ 1,850 K
  • Annual Income, $ -56,150 K
  • 36-Month Beta 3.83
  • Price/Sales 123.42
  • Price/Cash Flow N/A
  • Price/Book 1.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.31
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +37.79%
on 11/02/18
5.59 -35.42%
on 10/17/18
-1.44 (-28.51%)
since 10/15/18
3-Month
2.62 +37.79%
on 11/02/18
7.72 -53.27%
on 08/31/18
-1.49 (-29.22%)
since 08/15/18
52-Week
2.62 +37.79%
on 11/02/18
8.59 -57.97%
on 01/31/18
+0.61 (+20.33%)
since 11/15/17

Most Recent Stories

More News
Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in...

ADVM : 3.60 (+1.12%)
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 13.33% and 205.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

ADVM : 3.60 (+1.12%)
Adverum Biotechnologies: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Adverum Biotechnologies Inc. (ADVM) on Thursday reported a loss of $21 million in its third quarter.

ADVM : 3.60 (+1.12%)
Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today reported financial results for the third quarter...

ADVM : 3.60 (+1.12%)
Investor Expectations to Drive Momentum within Consolidated Edison, MUELLER WATER PRODUCTS, Adverum Biotechnologies, Buckeye Partners, inTest, and Live Nation Entertainment -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Consolidated Edison Inc (NYSE:ED),...

ADVM : 3.60 (+1.12%)
MWA : 10.84 (+0.93%)
INTT : 6.51 (-0.31%)
LYV : 54.25 (+1.27%)
ED : 76.95 (-3.11%)
BPL : 32.06 (+0.75%)
Adverum Biotechnologies (ADVM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADVM : 3.60 (+1.12%)
Adverum Biotechnologies Provides Program Updates

-- Preliminary data from the ADVANCE Phase 1/2 Study in A1AT deficiency showed ADVM-043 in doses of up to 1.5 x 10 vg/kg were safely administered and well tolerated; Protein expression did not meet a clinically...

ADVM : 3.60 (+1.12%)
Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the promotion of Leone Patterson as...

ADVM : 3.60 (+1.12%)
Adverum Biotechnologies Announces Data Presented at the European Society of Gene and Cell Therapy (ESGCT)

-- In an NHP model, ADVM-022 provided ocular expression of aflibercept at therapeutic levels equivalent to current standard of care

ADVM : 3.60 (+1.12%)
Consolidated Research: 2018 Summary Expectations for Mimecast, Shiloh Industries, Adverum Biotechnologies, AngioDynamics, Kimball Electronics, and Changyou -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Mimecast Limited (NASDAQ:MIME),...

MIME : 36.96 (+3.76%)
CYOU : 18.66 (+1.80%)
ADVM : 3.60 (+1.12%)
KE : 17.51 (+1.80%)
ANGO : 21.04 (+2.14%)
SHLO : 8.22 (+1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADVM with:

Business Summary

Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California.

See More

Key Turning Points

2nd Resistance Point 3.92
1st Resistance Point 3.74
Last Price 3.60
1st Support Level 3.46
2nd Support Level 3.36

See More

52-Week High 8.59
Fibonacci 61.8% 6.31
Fibonacci 50% 5.61
Fibonacci 38.2% 4.90
Last Price 3.60
52-Week Low 2.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar